Epiminder Ltd (EPI) Fair Value & Analysis

Healthcare · AU · Market cap A$74.8K (≈ $53.8K) · ISIN AU0000432239

Below-average quality, trading 19% below our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• Solid quality (46/100) at a price below fair value, the discount is the argument here, not the business quality.
• A fairly wide model range (A$0.2864 to A$0.5425) leaves room in how you read the outcome.
• Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Price vs Fair Value (9 months)

White line = price, green steps = our fair value per fiscal year. As of Aug 13, 2026.

How to read this chart

9‑month range A$0.2550 – A$1.31 · fair‑value band A$0.2864 – A$0.5425 · the A$0.3500 price screens below the A$0.4340 fair value. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Epiminder Ltd (EPI) currently trades at A$0.3500, while our model-based Fair Value estimate is A$0.4340, implying the stock looks roughly 24.0% undervalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Trailing-twelve-month revenue stands at A$648K. Revenue grew 89.8% year over year. Fundamentals as of Aug 13, 2026

Our scenario range runs from A$0.2864 (bear case) to A$0.5425 (bull case); at A$0.3500, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 77% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at 24%, EPI screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Epiminder Limited develops and manufactures a monitoring device to improve treatment of patients suffering with epileptic seizures and related conditions. It offers Minder system, an implantable sub scalp electroencephalography (EEG) monitoring system which is designed for continuous monitoring of brain activity.

Full company description

Epiminder Limited develops and manufactures a monitoring device to improve treatment of patients suffering with epileptic seizures and related conditions. It offers Minder system, an implantable sub scalp electroencephalography (EEG) monitoring system which is designed for continuous monitoring of brain activity. The company's Minder system comprises Minder implant, a sub scalp electrode with multiple recording points which enables capture of EEG continuously for months or years; Minder wearable, which receives and stores EEG recordings wirelessly transmitted from the Minder implant to the Minder app; Minder app that collects and transmits EEG data from the Minder implant via Bluetooth and uploads to the Minder cloud for processing; and Minder cloud, a secure, online portal which allows healthcare professionals to download patient data. Epi-Minder Pty Ltd was incorporated in 2017 and is based in Melbourne, Australia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2023 – FY2025 · reported fiscal years

Epiminder Ltd reported revenue of A$445K in FY2025 versus A$5.5M in FY2023, a compound −71.5%/yr. Reported net income was −A$31.8M in FY2025.

Watch EPI: get an alert when its fair value changes →

Peer Group

Medical Devices · 363 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Devices median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.